|
|
Article: Genaera Presents EVIZON(TM) Overview and New Trodusquemine Data at Fortis Bank Biotechnology Conference.
- Article from:
- PR Newswire
- Article date:
- April 26, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PLYMOUTH MEETING, Pa., April 26 /PRNewswire-FirstCall/ -- Genaera Corporation today presented an overview of its development pipeline, including recently announced data on bilateral visual acuity in subjects from Phase II trials of EVIZON(TM) (squalamine lactate) for the treatment of wet age-related macular degeneration (AMD) and promising new pre- clinical data on trodusquemine (MSI-1436), an anti-obesity compound. The data was presented by Genaera's President and Chief Executive Officer, John L. (Jack) Armstrong, Jr. at the 6th Annual Fortis Bank Biotechnology Conference in London, UK.
Mr. Armstrong reviewed previously announced results from Phase II clinical ...